Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases

NCT00579111 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00579111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00579111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2007
Completion date
October 31, 2010
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, hematologic diseases, lymphoproliferative disorders, multiple myeloma, myelodysplastic and myeloproliferative disorders, plasma cell dyscrasia